1. Am J Respir Crit Care Med. 2021 Feb 1;203(3):381-385. doi: 
10.1164/rccm.202008-3176LE.

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer 
in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results 
of an Open-Label Phase 3 Clinical Trial.

Griese M(1)(2), Costa S(3), Linnemann RW(4), Mall MA(5)(6), McKone EF(7), 
Polineni D(8), Quon BS(9)(10), Ringshausen FC(11)(12), Taylor-Cousar JL(13), 
Withers NJ(14), Moskowitz SM(15), Daines CL(16).

Author information:
(1)Ludwig Maximilians University Munich, Germany.
(2)German Center for Lung Research Munich, Germany.
(3)University of Messina Messina, Italy.
(4)Emory University Atlanta, Georgia.
(5)Charité-Universitätsmedizin Berlin Berlin, Germany.
(6)German Center for Lung Research Berlin, Germany.
(7)St. Vincent's University Hospital Dublin, Ireland.
(8)University of Kansas Medical Center Kansas City, Kansas.
(9)University of British Columbia Vancouver, British Columbia, Canada.
(10)St. Paul's Hospital Vancouver, British Columbia, Canada.
(11)Hannover Medical School Hannover, Germany.
(12)German Center for Lung Research Hannover, Germany.
(13)National Jewish Health Denver, Colorado.
(14)Royal Devon and Exeter NHS Foundation Trust Exeter, United Kingdom.
(15)Vertex Pharmaceuticals Incorporated Boston, Massachusetts and.
(16)University of Arizona Tucson, Arizona.

DOI: 10.1164/rccm.202008-3176LE
PMCID: PMC8020728
PMID: 32969708 [Indexed for MEDLINE]